) recently announced a strategic deal with Five Prime
Therapeutics, Inc. for the discovery of innovative biologics
targets and therapeutics for fibrosis-related inflammatory
diseases and central nervous system (CNS) disorders.
As per the agreement, Five Prime will receive roughly $16 million
in the form of an upfront fee, technology access fees, research
funding and success-based research milestone payments.
Additionally, Five Prime could receive exercise fees, product
related milestone payments as well as tiered royalties.
UCB and Five Prime will work together to design assays to screen
Five Prime's 5600 functional secreted proteins and transmembrane
receptor proteins (ligand traps).
Five Prime will use its technology platforms in this
collaboration to discover potential drug targets and candidates
for fibrosis-related inflammatory diseases and CNS diseases. UCB
has the right to license selected protein targets discovered in
This is the second collaboration announced by UCB in the past few
weeks. In Feb 2013, UCB entered into an agreement with ConfometRx
for the discovery of novel medicines in the neuroscience
therapeutic area. This research and development (R&D)
collaboration, spanning two years, will harness structural
biology to gain insight into G protein coupled receptors (GPCRs)
modulation in making drugs.
UCB carries a Zacks Rank #1 (Strong Buy). We expect Cimzia,
Vimpat and Neupro to continue performing well in 2013. A few
weeks back, Vimpat was approved in the European Union (EU) as a
single loading dose option for treating patients suffering from
partial onset seizures. Additionally, UCB announced new
regulatory filings with the US Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) for two additional
indications for Cimzia.
Currently, companies like
Lannett Company, Inc.
WuXi Pharma Tech (Cayman) Inc.
) also carry a Zacks Rank #1.
LANNETT INC (LCI): Free Stock Analysis Report
QLT INC (QLTI): Free Stock Analysis Report
UCB SA (UCBJF): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.